| Date Filed | Type | Description |
| 10/03/2023 |
4
| Nunes Anne (SVP, Chief Operations Officer) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 732 shares
@ $18.63, valued at
$13.6k
Exercised 2,491 restricted stock units
@ $0 |
|
| 08/17/2023 |
SC 13D
| Caligan Partners LP reports a 6.2% stake in Anika Therapeutics, Inc. |
| 08/11/2023 |
4
| Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,133 shares
@ $18.58, valued at
$21.1k
Exercised 3,859 restricted stock units
@ $0 |
|
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
4
| VOGT SUSAN L N (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| Thompson Jeffery S (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| Richard Stephen (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| Larsen Glenn R. (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| HENNEMAN JOHN B III (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| Fischetti Gary P (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 06/16/2023 |
4
| CONLEY SHERYL L (Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Granted 6,500 shares
@ $0 |
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2023 |
4
| Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 10,900 shares
@ $26.34, valued at
$287.1k
Exercised 24,575 restricted stock units
@ $0 |
|
| 04/28/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/13/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 03/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/27/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
4
| Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 2,609 shares
@ $26.1, valued at
$68.1k
Exercised 8,888 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Colleran David (EVP, General Counsel, Corp Sec) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 2,250 shares
@ $26.1, valued at
$58.7k
Exercised 7,663 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 13,211 shares
@ $26.1, valued at
$344.8k
Exercised 30,060 restricted stock units
@ $0 |
|
| 03/10/2023 |
4
| Levitz Michael L (EVP, CFO, Treasurer) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,303 shares
@ $26.91, valued at
$35.1k
Granted 17,624 restricted stock units
@ $0
Granted 38,475 options to buy
@ $0
Exercised 4,439 restricted stock units
@ $0 |
|
| 03/10/2023 |
4
| Colleran David (EVP, General Counsel, Corp Sec) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,081 shares
@ $26.91, valued at
$29.1k
Granted 16,395 restricted stock units
@ $0
Granted 35,790 options to buy
@ $0
Exercised 3,683 restricted stock units
@ $0 |
|
| 03/10/2023 |
4
| Blanchard Cheryl R (President, CEO, Director) has filed a Form 4 on Anika Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,232 shares
@ $26.91, valued at
$113.9k
Granted 60,004 restricted stock units
@ $0
Granted 130,998 options to buy
@ $0
Exercised 14,419 restricted stock units
@ $0 |
|
|